CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma
Yen-Hsiang Huang, Kuo-Hsuan Hsu, Chun-Shih Chin, Jeng-Sen Tseng, Tsung-Ying Yang, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J.W. Chen, Gee-Chen Chang
Cancer Research and Treatment. 2022;54(2):434-444.   Published online 2021 August 2    DOI: https://doi.org/10.4143/crt.2021.671

Excel Download

The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma
Cancer Research and Treatment. 2022;54(2):434-444   Crossref logo
Link1 Link2 Link3

EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with multiple brain metastases
Annals of Oncology. 2019;30:ii69-ii70   Crossref logo
Link1 Link2 Link3

P48.10 Efficacy of EGFR-TKIs vs TKIs Plus Chemotherapy as First-Line Treatment in EGFR-Mutation Lung Adenocarcinoma With Liver Metastases
Journal of Thoracic Oncology. 2021;16(10):S1110   Crossref logo
Link1 Link2

P76.51 ERĪ²1 Expression Patterns have Different Effects on EGFR TKIs Treatment Response in EGFR Mutant Lung Adenocarcinoma.
Journal of Thoracic Oncology. 2021;16(3):S609-S610   Crossref logo
Link1 Link2

MA12.08 Chemotherapy plus EGFR TKIs or Bevacizumab versus Chemotherapy Alone in SCLC-Transformed EGFR-Mutant Lung Adenocarcinoma
Journal of Thoracic Oncology. 2021;16(3):S178-S179   Crossref logo
Link1 Link2

Exon 19 deletion was associated with better survival outcomes in advanced lung adenocarcinoma with mutant EGFR treated with EGFR-TKIs as second-line therapy after first-line chemotherapy: a retrospective analysis of 128 patients
Clinical and Translational Oncology. 2015;17(9):727-736   Crossref logo
Link1 Link2 Link3

Efficacy Differences of First-line EGFR-TKIs Alone vs. in Combination with Chemotherapy in Advanced Lung Adenocarcinoma Patients with Sensitive EGFR Mutation and Concomitant Non-EGFR Genetic Alteration(s)
. 2021;   Crossref logo
Link1 Link2

Efficacy of pemetrexed and carboplatin with or without bevacizumab in lung adenocarcinoma patients with EGFR non-T790M mutations after progression on first-line EGFR-tyrosine kinase inhibitors
Thoracic Cancer. 2018;9(9):1151-1155   Crossref logo
Link1 Link2

Metformin plus EGFR TKIs for lung adenocarcinoma
The Lancet Oncology. 2019;20(10):e563   Crossref logo
Link1 Link2

Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis
BMC Cancer. 2019;19(1):   Crossref logo
Link1 Link2 Link3

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.